Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study

Documenti analoghi

• Effectiveness of the 2023 Autumn XBB.1.5 COVID‐19 Booster During Summer 2024 in the EU/EEA: A VEBIS Electronic Health Record Network Study
  di: James Humphreys, et al.
  Pubblicazione: (2025)
• Early COVID‐19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024
  di: Liliana Antunes, et al.
  Pubblicazione: (2024)
• Effectiveness of the XBB.1.5 COVID‐19 Vaccines Against SARS‐CoV‐2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024
  di: Liliana Antunes, et al.
  Pubblicazione: (2025)
• Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS‐CoV‐2 Infection in Older Adults During the JN.1 Lineage‐Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024
  di: Lore Merdrignac, et al.
  Pubblicazione: (2024)
• Immune escape of BA.2.86 is comparable to XBB subvariants from the plasma of BA.5‐ and BA.5‐XBB‐convalescent subpopulations
  di: Xiaoyun Yang, et al.
  Pubblicazione: (2024)